Márta Venczel

Márta Venczel

Auto-generated profile, based on publicly available information

Márta Venczel

Sanofi, Global CMC Development, Sanofi-Aventis Deutschland GmbH, Frankfurt/Main, Germany

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 April 2022 in Journal of Pharmaceutical Sciences
Verified
Journal Article
Open access
CBChristian Bender
Christian Bender
SESabine Eichling
Sabine Eichling
LFLutz Franzen
Lutz Franzen
VHViktoria Herzog
Viktoria Herzog
LILudger M. Ickenstein
Ludger M. Ickenstein
SZShalin Zenk
Shalin Zenk
For injectable biopharmaceuticals, the subcutaneous route of administration is increasingly preferred over intravenous administration. However, one of the challenges in the development of subcutaneously administered biopharmaceuticals is a reduced bioavailability, which is difficult to predict. Since animal models do not reliably reflect bioavailability in patients, in vitro models could help to develop drug candidates. The purpose of this study was to evaluate a versatile set of in vitro tools for their suitability to predict bioavailability of biopharmaceuticals after subcutaneous administration. We examined seven commercially available biopharmaceuticals using three instruments, i.e., the Subcutaneous Injection Site Simulator (Scissor), the Osmomat 050, and a dialysis system using three artificial extracellular matrices, two dissolution apparatuses, i.e., the USP4 and the USP7, and two evaluation tools, i.e., the affinity-capture self-interaction nanoparticle spectroscopy (AC-SINS) and the Developability Index (DI). Results were evaluated for their usefulness to predict the bioavailability and other pharmacokinetic parameters in humans using the Pearson correlation. None of the tested instruments and methods could reliably approximate bioavailability. Only pressure values derived with the Osmomat 050 instrument correlated with Cmax with a Pearson correlation coefficient greater than 0.8. No single in vitro method confidently predicted the bioavailability in humans. We only found a correlation to maximum plasma concentration values for one of the tested approaches. However, a more focused evaluation would be necessary to confirm our findings and test combinations of orthogonal methods that may improve the confidence of such a prediction.

30 March 2023 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
ITIria Torres-Terán
Iria Torres-Terán
MVMárta Venczel
Márta Venczel
TSTatjana Stieler
Tatjana Stieler
LPLaura Parisi
Laura Parisi
AKAlla Kloss
Alla Kloss
SKSandra Klein
Sandra Klein

13 May 2024 in International Journal of Pharmaceutics
Verified
Journal Article
Open access
ITIria Torres-Terán
Iria Torres-Terán
MVMárta Venczel
Márta Venczel
SKSandra Klein
Sandra Klein
Media that mimic physiological fluids at the site of administration have proven to be valuable in vitro tools for predicting in vivo drug release, particularly for routes of administration where animal studies cannot accurately predict human performance. The objective of the present study was to develop simulated interstitial fluids (SISFs) that mimic the major components and physicochemical properties of subcutaneous interstitial fluids (ISFs) from preclinical species and humans, but that can be easily prepared in the laboratory and used in in vitro experiments to estimate in vivo drug release and absorption of subcutaneously administered formulations. Based on data from a previous characterization study of ISFs from different species, two media were developed: a simulated mouse-rat ISF and a simulated human-monkey ISF. The novel SISFs were used in initial in vitro diffusion studies with a commercial injectable preparation of liraglutide. Although the in vitro model used for this purpose still requires significant refinement, these two new media will undoubtedly contribute to a better understanding of the in vivo performance of subcutaneous injectables in different species and will help to reduce the number of unnecessary in vivo experiments in preclinical species by implementation in predictive in vitro models.

10 February 2012 in Crystal Growth & Design
Verified
Journal Article
Closed access
MVMárta Venczel
Márta Venczel
ISIda Szvoboda
Ida Szvoboda
BPBenjámin Podányi
Benjámin Podányi
DVDelphine Valente
Delphine Valente
JMJerome Menegotto
Jerome Menegotto
GUGabriella Ujhelyi
Gabriella Ujhelyi

14 March 2024 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
TSTim A. Schöner
Tim A. Schöner
VVVerena Vogel
Verena Vogel
MVMarta Venczel
Marta Venczel
KKKatharina Knoth
Katharina Knoth
WKWalter Kamm
Walter Kamm
CLClaus-Michael Lehr
Claus-Michael Lehr

21 November 2025 in Journal of Controlled Release
Verified
Journal Article
Closed access
GSGerd Schwagerle
Gerd Schwagerle
Rodolfo Hernandes BonanRodolfo Hernandes Bonan
Rodolfo Hernandes Bonan
MMMikolaj Milewski
Mikolaj Milewski
MSManuel Sanchez-Felix
Manuel Sanchez-Felix
SMSachin Mittal
Sachin Mittal
MVMarta Venczel
Marta Venczel